Clinical Trial Update: Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating alpha-emitting versus beta-emitting radionuclide therapy in combination with metastasis-directed stereotactic body radiot…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Investigational alpha-emitting radionuclide therapy
• Investigational beta-emitting radionuclide therapy

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Oligometastatic Prostate Adenocarcinoma, Recurrent Prostate Adenocarcinoma | Phase 2 | Status: RECRUITING